Novartis’ Ianalumab Provides Sustained Disease Control in Immune Thrombocytopenia Patients with Just Four Monthly Doses Novartis today announced positive results from VAYHIT2, a Phase III trial evaluating ianalumab plus eltrombopag in…
Roche Introduces New CE-Marked PCR Test to Enhance Diagnostic Accuracy for Women with Vaginitis Roche announced today the CE Mark for its cobas® BV/CV (Bacterial Vaginosis/Candida Vaginitis) assay to accurately…
Phase 3 MajesTEC-3 Study Delivers Unprecedented Results, Positioning TECVAYLI® Plus DARZALEX FASPRO® as a Potential New Standard of Care as Early as Second-Line Treatment for Relapsed/Refractory Multiple Myeloma Johnson &…
Lilly to Invest $6 Billion in Alabama Facility for Active Pharmaceutical Ingredient Production Eli Lilly and Company today announced plans to invest more than $6 billion in a new manufacturing facility in Huntsville, Alabama.…
Jim Lang Elected to Halozyme’s Board of Directors Halozyme Therapeutics, Inc. today announced the election of Jim Lang to its Board of Directors. Mr. Lang brings more than 30 years of…
Global health leaders convene at the IAEA headquarters in Vienna this week to advance radiation safety in medicine The International Conference on Radiation Protection in Medicine: X Ray Vision, organized by…
Genmab Unveils New Phase 1b/2 EPCORE® CLL-1 Data Showcasing Epcoritamab’s Promise as Monotherapy and in Combination for Richter Transformation Patients Genmab A/S today announced new and updated data from three arms of the ongoing Phase 1b/2 EPCORE® CLL-1 trial evaluating the efficacy and…
BRUKINSA Achieves Landmark 74% Six-Year Progression-Free Survival in Treatment-Naïve Chronic Lymphocytic Leukemia Patients BeOne Medicines Ltd., a global oncology company, reaffirms its position as the leader in chronic lymphocytic leukemia…
Bristol Myers Squibb reinforces its hematology leadership through new research across multiple therapies for patients with lymphoma at the 67th American Society of Hematology (ASH) Annual Meeting. Highlights include updates…
Roche Highlights Lunsumio Data Demonstrating Promise in Earlier Treatment Settings for Both Indolent and Aggressive Lymphomas Roche announced today new data highlighting the potential of Lunsumio® (mosunetuzumab) in earlier treatment…
Blueprint Medicines presents long-term AYVAKIT® benefits in indolent and advanced systemic mastocytosis at ASH 2025. Blueprint Medicines, a Sanofi company, today announced updated data reinforcing the clinical efficacy and safety of…
Johnson & Johnson’s INLEXZO™ (Gemcitabine Intravesical System) Achieves 74% Disease-Free Survival at One Year in Patients with BCG-Unresponsive, High-Risk, Papillary-Only NMIBC Johnson & Johnson announced today that new data from…